StocksTelegraph
S&P 500—NASDAQ—DOW—RUSSELL—
NASDAQ · OLMA·Healthcare

Olema Pharmaceuticals, Inc. Stock Analysis & AI Score

Olema Pharmaceuticals, Inc. (OLMA) has an ST Score of 47.5 (C+), driven by its Financial Strength (A) and held back by its Growth (F). Analysts rate it Buy with a $28.33 price target (+213.4% upside).

Market Closed
$9.04
Prev Close
—
Market Cap
—
Day Range
—
52W Range
—
P/E
—
EPS (TTM)
—
Volume
—
Avg —
Beta
—
48
ST Score
47.5/100C+

Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.

As of
AI Daily Briefing
Analysis by AI
Price History
—
Technical Indicators
FMP
Earnings Surprises
Analyst Forecast
Revenue Mix

Company Information

Employees—
CEO—
SectorHealthcare
IndustryBiotechnology
IPO Date—
Website—
Country—
ExchangeNASDAQ

SEC Filings

Annual Report (10-K)

Filing DateAcceptedLink
Loading…

Quarterly Report (10-Q)

Filing DateAcceptedLink
Loading…
Analyst Price Target
ESG Score
Latest News

ST Score

OLMA
47.5out of 100
Grade C+

Olema Pharmaceuticals, Inc. (OLMA) has an ST Score of 47.5 (C+), driven by its Financial Strength (A) and held back by its Growth (F). Analysts rate it Buy with a $28.33 price target (+213.4% upside).

Strongest
Financial StrengthA
Weakest
GrowthF
All factor grades
  • Financial StrengthA
  • ForecastA
  • ValuationB
  • ProfitabilityC+
  • MomentumD+
  • GrowthF
  • Piotroski2/9
Score methodology
Press Releases

Contact

OLMA stock: frequently asked questions

What is OLMA's ST Score?

Olema Pharmaceuticals, Inc. (OLMA) has an ST Score of 47.5 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Is OLMA a buy, hold, or sell?

Analysts rate OLMA a Buy, with a price target of $28.33 (+213.4% vs the current price). Our ST Score grades it C+ (47.5/100). The ST Score is a data-driven signal, not a recommendation.

What are OLMA's factor grades?

Valuation B, Profitability C+, Financial Strength A, Momentum D+, Growth F, Forecast A.

What is OLMA's valuation grade?

Olema Pharmaceuticals, Inc. (OLMA) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

What is OLMA's growth grade?

Olema Pharmaceuticals, Inc. (OLMA) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

What is OLMA's profitability grade?

Olema Pharmaceuticals, Inc. (OLMA) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

What is OLMA's financial strength grade?

Olema Pharmaceuticals, Inc. (OLMA) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

What is the analyst price target for OLMA?

The average analyst price target for Olema Pharmaceuticals, Inc. (OLMA) is $28.33 from 9 analysts, which is +213.4% versus the recent price of $9.04.

What is OLMA's Piotroski score?

Olema Pharmaceuticals, Inc. (OLMA) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.